Here’s what you should know:
1, Envision’s board rejected offers of $45.25 per share and $45.75 per share before agreeing to a $46 per share offer.
2. Envision shareholders approved the sale last week. It still must clear the Securities and Exchange Commission.
3. Once the sale closes, KKR will take Envision private.
4. Envision CEO Chris Holden will remain CEO after the sale. He said KKR won’t change how the company operates.
More articles on transactions/valuation:
Envision loses another contract over out-of-network billing & more — 11 ASC company key notes
Total charges for top 10 procedures performed at ASCs in the Northeast
10 strategies to streamline ASC supply chain management
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.